China Pharma completes of trials of rosuvastatin planning to commercialize generic Crestor in domestic market
Haikou City-based China Pharma Holdings (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, says it has completed clinical trials of the cholesterol-lowering drug, rosuvastatin (a generic version of AstraZeneca’s Crestor), which the company intends to commercialize in the large and expanding Chinese healthcare market.
In the Chinese firm’s clinical trials, rosuvastatin demonstrated better effect in lowering low-density lipoprotein cholesterol compared to control groups using atorvastatin (Pfizer’s Lipitor). A 10mg dose of rosuvastatin lowered LDL-C by 45% and helped 82% of all subjects reach LDL-C treatment target levels.
In a statement on the situation to The Pharma Letter, AstraZeneca said: “We are aware that rosuvastatin generics exist in China. However, outside of China AstraZeneca has full confidence in its intellectual property protecting Crestor and will defend it vigorously.”
9 billion renminbi market sector
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze